Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories reported a 17% year-over-year increase in revenue for the second quarter, reaching ₹80,162 million, driven by strong growth in global generics and emerging markets. Despite the rise in revenues, the company faced a decline in profit after tax attributable to equity holders, which fell by 15% year-over-year. The Board also approved a significant investment in its Russian subsidiary to support working capital needs, reflecting its ongoing commitment to strengthening core businesses and expanding market presence.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- The “Hidden Costs” of Apple (NASDAQ:AAPL) Intelligence
- Lyft (NASDAQ:LYFT) Surges After New Deal With Mobileye
- Planet Fitness (NYSE:PLNT) Stock Rises on Blink Holdings Buyout Plan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
